Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Debt Ratio (2020 - 2023)

Candel Therapeutics' Debt Ratio history spans 4 years, with the latest figure at 0.41 for Q3 2023.

  • For Q3 2023, Debt Ratio rose 72.48% year-over-year to 0.41; the TTM value through Sep 2023 reached 0.41, up 72.48%, while the annual FY2022 figure was 0.26, 4042.14% up from the prior year.
  • Debt Ratio for Q3 2023 was 0.41 at Candel Therapeutics, up from 0.35 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.41 in Q3 2023 and bottomed at 0.01 in Q4 2021.
  • The 4-year median for Debt Ratio is 0.24 (2022), against an average of 0.22.
  • The largest annual shift saw Debt Ratio tumbled 48.09% in 2021 before it soared 4042.14% in 2022.
  • A 4-year view of Debt Ratio shows it stood at 0.01 in 2020, then crashed by 48.09% to 0.01 in 2021, then skyrocketed by 4042.14% to 0.26 in 2022, then skyrocketed by 57.01% to 0.41 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Debt Ratio are 0.41 (Q3 2023), 0.35 (Q2 2023), and 0.3 (Q1 2023).